Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a  narrative review

ConclusionRT in combination with systemic therapy remains the established first-line treatment for low-burden mHSPC, though the exact definition of low metastatic burden remains contentious. Precise assessment of metastatic burden is vital to identify patients who would derive the greatest benefit from RT. As treatment paradigms evolve, embracing multimodal approaches holds potential for optimizing outcomes in patients with mHSPC. Further research is needed to solidify the role of cRP as a  standard therapeutic approach and to refine treatment strategies for improved patient outcomes.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research